Opinion
Video
Author(s):
Bladder cancer specialists discuss their strategies for monitoring patients with BCG-unresponsive non–muscle invasive bladder cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
Durvalumab plus BCG significantly improves DFS in NMIBC
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
FDA to host advisory committee meeting on UGN-102 for NMIBC
FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy
Published data support safety, efficacy of vaginal insert for SUI
Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer